1-3 of 3
Robert D. Annett
Close
Sort by
Journal Articles

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

CME Clinical Trials & Observations Brief Report
Robert J. Hayashi, Michelle L. Hermiston, Brent L. Wood, David T. Teachey, Meenakshi Devidas, Zhiguo Chen, Robert D. Annett, Barbara L. Asselin, Keith August, Steve Cho, Kimberly P. Dunsmore, Jason Lawrence Freedman, Paul J. Galardy, Paul Harker-Murray, Terzah M. Horton, Alok Jaju, Allison Lam, Yoav H. Messinger, Rodney R. Miles, Maki Okada, Samir Patel, Eric S. Schafer, Tal Schechter, Kristin A. Shimano, Neelam Singh, Amii Steele, Maria L. Sulis, Sarah L. Vargas, Stuart S. Winter, Charlotte Wood, Patrick A. Zweidler-McKay, Mignon L. Loh, Stephen P. Hunger, Elizabeth A. Raetz, Catherine M. Bollard, Carl E. Allen
Journal: Blood
Blood (2024) 143 (20): 2053–2058.
https://doi.org/10.1182/blood.2023021184
Published: 2024
Includes: Supplemental data
Journal Articles

Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231

Robert J. Hayashi, Michelle L. Hermiston, David T. Teachey, Meenakshi Devidas, Brent L. Wood, Zhiguo Chen, Robert D Annett, Barbara L Asselin, Keith J August, Steve Y Cho, Kimberly P. Dunsmore, Jason L. Freedman, Paul J. Galardy, Paul Harker-Murray, Terzah M. Horton, Alok I Jaju, Allison Lam, Yoav H. Messinger, Rodney R. Miles, Maki Okada, Samir I Patel, Eric S Schafer, Tal Schechter-Finkelstein, Kristin A. Shimano, Neelam Singh, Amii C. Steele, Maria Luisa Sulis, Sarah L Vargas, Stuart S. Winter, Charlotte Wood, Patrick A Zweidler-McKay, Mignon L. Loh, Stephen P. Hunger, Elizabeth A. Raetz, Catherine M Bollard, Carl Allen
Journal: Blood
Blood (2022) 140 (Supplement 1): 6387–6389.
https://doi.org/10.1182/blood-2022-159694
Published: 2022
Journal Articles

Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231

David T. Teachey, MD, Meenakshi Devidas, PhD, Brent L Wood, MD PhD, Zhiguo Chen, MS, Robert James Hayashi, MD, Robert D Annett, PhD, Barbara L Asselin, MD, Keith J August, MDMS, Steve Y Cho, MD, Kimberly P. Dunsmore, MD, Brian T. Fisher, DO, MSCE, Jason L. Freedman, MD, Paul J. Galardy, MD, Paul Harker-Murray, MD PhD, Michelle L. Hermiston, MD PhD, Terzah M Horton, MD PhD, Alok I Jaju, MD, Allison Lam, BCPS, Yoav H. Messinger, MD, Rodney R. Miles, MD PhD, Maki Okada, RN, Samir I Patel, MD, Eric S. Schafer, MD MHS, Tal Schechter-Finkelstein, MD, Kristin A. Shimano, MD, Neelam Singh, PhD, Amii C. Steele, PhD, Maria L. Sulis, MD, Sarah L Vargas, PhD, Stuart S. Winter, MD, Charlotte Wood, CCRP, Patrick Zweider McKay, MDPhD, Catherine M. Bollard, MD MBChB, Mignon L. Loh, MD, Stephen P. Hunger, MD, Elizabeth A. Raetz, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-134730
Published: 2020